Poor R-Wave Progression and Long-Term Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)

Brief title: Poor R-Wave Progression in MESA Outcomes

José Nunes de Alencar[1,2], Sandro Pinelli Felicioni[1], Mariana Fuziy Nogueira De Marchi[1].

1. Electrocardiography Unit. Instituto Dante Pazzanese de Cardiologia. São Paulo. Brazil.
2. Research Division. Instituto Dante Pazzanese de Cardiologia. São Paulo. Brazil.

Data availability statement: De-identified MESA data from Exams 1–5 with adjudicated events through calendar year 2015 are available from the NHLBI BioLINCC repository (Accession HLB00640824a) upon approved application and data-use agreements. Access for commercial entities is tiered per participant consent.

Conflicts of Interest Disclosure: There is no conflict of interest to disclose.

Ethics approval: All participants provided written informed consent and the protocol was approved by the institutional review boards of each participating center.

Clinical trial registration: ClinicalTrials.gov Identifier NCT00005487.

Total word Count: 4683

CORRESPONDING AUTHOR

José Nunes de Alencar Neto

Instituto Dante Pazzanese de Cardiologia

Avenida Dr. Dante Pazzanese No. 500, Vila Mariana

São Paulo 04012-091

Brazil

Tel: +551150856457

31 jose.alencar@dantepazzanese.org.br

Clinical Perspective

What Is New?

• In a multi-ethnic, CAD-free community cohort (MESA; n=6,323), isolated poor

R-wave progression (PRWP) was uncommon (3.2%) and not independently

associated with all-cause mortality or MACE over 14 years.

• Prior positive reports from single-ethnicity cohorts likely reflect coexisting

coronary disease and smoking-/lung-related voltage effects rather than a direct

prognostic signal of PRWP itself.

What Are the Clinical Implications?

• Isolated PRWP on a baseline ECG, in the absence of clinical CAD or

structural heart disease, should not trigger additional cardiac testing solely on

the basis of this pattern.

• Future work should disentangle technical (lead placement) and pulmonary

influences on anterior voltages and reassess PRWP's diagnostic utility for prior

MI and cardiomyopathies with modern reference standards.

ABSTRACT

Background: Poor R-wave progression (PRWP) on the 12-lead electrocardiogram has been linked to excess mortality in single-ethnicity cohorts, but its significance in a contemporary, multi-ethnic population without baseline coronary artery disease (CAD) is unknown. We examined the prevalence and prognostic value of isolated PRWP in the Multi-Ethnic Study of Atherosclerosis (MESA).

Methods: MESA enrolled 6,814 adults aged 45–84 years free of clinical cardiovascular disease. After exclusion of ECGs with pre-excitation, major conduction disturbances, Q-wave criteria for prior infarction, or missing covariates, 6,323 participants (mean age 61.9 ± 10.2 years; 54% women) were analyzed. PRWP was defined as an R-wave ≤ 3 mm in lead V3 with R V3 > R V2 and was present in 202 individuals (3.2%). Cox models adjusted for age, sex, race/ethnicity, hypertension, and diabetes assessed associations with all-cause mortality and major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, coronary revascularization, or heart-failure hospitalization).

Results: During a median follow-up of 14.1 years (IQR 13.5–14.7), 1,138 deaths and 918 MACE were adjudicated. PRWP was not associated with all-cause mortality in the prespecified model (hazard ratio [HR] 1.31, 95% CI 0.99–1.73; P = 0.059) nor with MACE (HR 1.29, 95% CI 0.93–1.79). Additional adjustment for current smoking and self-reported emphysema, both more common in PRWP, attenuated the mortality HR to 1.19 (95% CI 0.90–1.58) and MACE (HR 1.26, 95% CI 0.91–1.76). Interaction terms revealed no effect modification by sex or race/ethnicity.

Conclusion: In a large, multi-ethnic cohort free of clinical CAD, isolated PRWP did not confer independent risk for all-cause death or major cardiovascular events over 14 years. Prior positive studies may reflect populations enriched for overt coronary disease or other high-risk features rather than a direct effect of the ECG pattern itself.

Keywords: poor R-wave progression, electrocardiography, multi-ethnic cohort, cardiovascular mortality, MESA

INTRODUCTION

Evidence from disease-specific cohorts suggests that poor R wave progression (PRWP) may lead to adverse outcomes. In the general population, the Health 2000 survey, a nationally representative Finnish cohort of 5,613 adults, demonstrated a 5.1% prevalence overall (7.0% in women vs. 2.7% in men). During a median of 5.8 years of follow-up, PRWP conferred a two-fold increase in both all-cause and cardiovascular mortality among women, an effect that persisted after adjustment for age, hypertension, diabetes, and established ischemic heart disease (adjusted HR 2.00, 95 % CI 1.28–3.13). In men, however, the association was attenuated and nonsignificant.(1) More recently, a 24-year community study linked PRWP to sudden cardiac death (SCD) (adjusted HR 2.13, 95% CI 1.34–3.39) and amplified cardiac-mortality risk among participants with known CAD.(2)

Despite these signals, a contemporary systematic review concluded that available studies suffer from heterogeneous PRWP definitions, inconsistent outcome ascertainment, and pervasive selection bias, impeding firm inferences about diagnostic accuracy.(3) The review underscored a need for large, multiethnic, community-based cohorts in which standardized ECG acquisition, rigorous adjudication of events, and comprehensive covariate adjustment could clarify the true prognostic weight of PRWP.

The Multi-Ethnic Study of Atherosclerosis (MESA) meets these criteria. Initiated in 2000, MESA enrolled 6814 adults aged 45–84 years who were free of clinical cardiovascular disease at baseline, intentionally sampling equal proportions of women and men across four self-identified race/ethnic groups—White, Black, Hispanic, and Chinese—from six U.S. field centers.(4) Uniform digital 12-lead ECGs, detailed imaging of subclinical atherosclerosis, and adjudicated cardiovascular events have been collected over two decades of surveillance. MESA therefore provides an unparalleled framework to investigate (a) the prevalence of PRWP in a multiethnic population initially free of overt heart disease, (b) the independent association between PRWP and subsequent all-cause death, cardiovascular death, and (c) potential effect modification by sex, race/ethnicity.

Accordingly, we used MESA to quantify its independent association with all-
cause mortality and major adverse cardiovascular events (MACE), and whether
any association is modified by sex.

METHODS

Study Population

MESA is a prospective, population-based cohort that enrolled 6,814 adults aged

45–84 yr who were free of clinically apparent cardiovascular disease at baseline

(July 2000–September 2002) from six U.S. field centers.(4) All participants gave

written informed consent, and each center's institutional review board approved

the protocol. Clinical cardiovascular disease (CVD) was an exclusion criterion

for the parent study; candidates reporting physician-diagnosed myocardial

infarction, angina, coronary revascularization, stroke or transient ischemic

attack, heart failure, pacemaker or ICD implantation, or valve surgery were

ineligible. Additional exclusions included body weight > 136 kg, active cancer

treatment, or plans to relocate within five years. All participants provided written

informed consent, and each field center's institutional review board approved

the protocol.

For the present analysis we used baseline data and censored follow-up at 31

December 2015. Participants were excluded if they had electrical confounders.

(a) ECGs labelled by Minnesota coding as Wolff–Parkinson–White were

discarded because pre-excitation alters initial depolarization vectors. (b) Those

showing complete bundle-branch block, bifascicular block or other major

intraventricular conduction delay were excluded for the same reason. (c)

Tracings annotated by the automated algorithm as "probable prior anterior

myocardial infarction" on the basis of pathologic Q waves were also removed,

as a deep Q wave prevents reliable identification of diminished R-wave growth.

Finally, (d) records missing any key covariate required for multivariable

adjustment (age, sex, diabetes status, hypertension status, or any relevant ECG

data) were excluded.

Electrocardiography and Definition of Poor R-Wave Progression

Standard 12-lead ECGs were recorded digitally at 25 mm/s and 10 mm/mV using a Marquette MAC-PC system (GE Healthcare). All tracings were transmitted electronically to the MESA ECG Reading Center (Wake Forest University), where certified analysts applied Minnesota coding; ≥ 97 % of leads met the protocol's quality threshold. R-wave amplitudes were measured automatically, and values for lead V3 were exported for analysis. PRWP was defined as an R-wave amplitude ≤ 0.30 mV (≤ 3 mm) in lead V3 and an R-wave amplitude in V3 that exceeded that in V2 (R V3 > R V2).

Covariate Assessment

Age, sex and race/ethnicity were self-reported at baseline. Blood pressure was obtained with a standardized protocol; hypertension was defined as systolic pressure ≥ 140 mm Hg, diastolic pressure ≥ 90 mm Hg, or use of antihypertensive medication. Diabetes was defined as fasting plasma glucose ≥ 126 mg/dL or use of glucose-lowering medication. Body-mass index was measured with standard MESA procedures. Baseline spirometry (FEV_1, FVC, FEV_6 and percent-predicted values) was available in a subset. Because spirometry does not quantify static lung volumes (e.g., total lung capacity or residual volume), it cannot diagnose pulmonary hyperinflation; therefore, we did not treat spirometric indices as direct measures of hyperinflation in the primary analyses.

Ascertainment of Outcomes

Participants or relatives were contacted every 9–12 months to identify hospitalizations and deaths; medical records were reviewed, and events were adjudicated by a centralized committee.(5) Outcomes for this analysis were (a) all-cause mortality and (b) MACE defined here as the composite of cardiovascular death, nonfatal myocardial infarction, coronary revascularization (percutaneous coronary intervention or coronary-artery bypass graft), and hospitalization for congestive heart failure.

Statistical Analysis

Continuous variables are reported as mean ± SD and compared with unpaired t-tests; categorical variables are summarized as counts (percentages) and compared with χ^2 tests. For baseline covariates, P values were generated from logistic-regression models adjusted for both age and sex.

Time-to-event analyses were performed with Cox proportional-hazards regression. The primary, prespecified model adjusted for age, sex, race/ethnicity, hypertension, and diabetes—covariates selected a priori. After reviewing the baseline data, we built a second, exploratory model adding characteristics that differed materially between PRWP and non-PRWP groups and that have biologic links to both precordial voltage and cardiovascular risk. Proportional-hazards assumptions were confirmed with Schoenfeld residuals. Effect modification by sex was assessed by adding a PRWP × sex interaction term and comparing nested models with a likelihood-ratio test; sex-specific hazard ratios (HRs) were taken from this interaction model. Given that previous research predominantly involved White Scandinavian cohorts, we also conducted an unplanned, exploratory analysis to assess the potential effect modification by self-identified race/ethnicity. A multiplicative PRWP × race term (four categories) was added to the fully adjusted Cox model and compared with the base model. All effects are reported as adjusted HRs with 95 % confidence intervals (CIs).

MACE were tallied hierarchically: cardiovascular death, then non-fatal myocardial infarction, followed by coronary revascularization (percutaneous coronary intervention or coronary-artery bypass graft), and finally hospitalization for heart failure. Each participant contributed only the first qualifying event. Two-by-two contingency tables compared event frequencies between PRWP cases and controls; Pearson's χ^2 test was used when all expected cell counts were ≥ 5, otherwise Fisher's exact test was applied.

To illustrate time-to-event differences after covariate adjustment, we generated survival curves directly from the fully adjusted Cox model (age, sex, race/ethnicity, hypertension, diabetes). The curves, shown with point-wise 95 % confidence bands, represent the survival that would be expected for each group if they shared an identical distribution of covariates. Because the

215 estimates are standardized across the full cohort, conventional numbers-at-risk
216 tables are not applicable.
217 Analyses were performed in R version 4.5.0 (R Foundation for Statistical
218 Computing). All reported P values are two-sided, and statistical significance
219 was defined as $P < 0.05$.
220

RESULTS

Participant Characteristics

Of 6,814 participants enrolled in MESA, we sequentially excluded 491 (1 Wolff-
Parkinson-White pattern, 297 bundle-branch or other major conduction
disturbances, 124 major Q-wave MIs, 69 missing key covariates), leaving 6,323
participants for analysis (Figure 1). The cohort's mean age was 61.9 ± 10.2
years; 3,427 were women (54.2 %) and 2,896 were men (45.8 %). Self-
identified race/ethnicity was 37.8 % White (n = 2,390), 27.7 % African American
(n = 1,750), 22.4 % Hispanic (n = 1,414), and 12.2 % Chinese American (n =
769).
Poor R-wave progression was present in 202 participants (3.2 %) overall—
136/3,427 women (4.0 %) and 66/2,896 men (2.3 %). Table 1 details other
baseline characteristics and univariate age/sex–adjusted comparisons between
the PRWP and non-PRWP groups. Relative to controls, PRWP cases were
more frequently current smokers (23 % vs 13 %) and were six-fold more likely
to report physician-diagnosed emphysema (7.9 % vs 1.3 %). They also had
marginally lower mean LDL-C (112 mg/dL vs 118 mg/dL) and slightly higher
HDL-C, but the absolute lipid differences were small (< 6 mg/dL) and not
considered clinically meaningful (Table 1).
240

Association of PRWP with Outcomes

242 During a median follow-up of 14.1 years (IQR, 13.5–14.7 years), we observed
243 1,138 deaths from any cause (18.0 %) and 918 adjudicated MACE (14.5 %),
244 comprising 315 cardiovascular deaths, 125 non-fatal myocardial infarctions, 264
245 coronary revascularizations, and 214 hospitalizations for heart failure. Among

participants with PRWP, there were 52 all-cause deaths (25.7 %) and 38 MACE (18.8 %). Hierarchical first-occurrence event counts, prioritized as cardiovascular death, nonfatal myocardial infarction, coronary revascularization, and heart failure hospitalization, are presented in Table 2. Model-adjusted survival curves for freedom from all-cause death and MACE are shown in Figures 2 and 3. In the prespecified model—adjusted for age, sex, race/ethnicity, hypertension, and diabetes—PRWP showed a borderline association with all-cause mortality (HR 1.31, 95 % CI 0.99–1.73; P = 0.059) and no clear association with MACE (HR 1.29, 95 % CI 0.93–1.79; P = 0.123).

Because smoking and emphysema differed materially between PRWP and non-PRWP groups and are biologically linked to both thoracic voltage and cardiovascular risk (through lung hyperinflation and modulation of long-term cardiovascular risk), an exploratory model added these two covariates. The hazard ratio for death fell to 1.19 (95 % CI 0.90–1.58, P = 0.229) and the estimate for MACE remained neutral (HR 1.26, 95 % CI 0.91–1.76, P = 0.163). Lipid fractions were not introduced into either model: their between-group differences were statistically significant but clinically trivial and lack a plausible mechanistic connection to anterior R-wave amplitude or to unmeasured confounding in this context.

Effect modification analysis

Addition of a PRWP × sex interaction term to the prespecified model did not improve model fit (likelihood-ratio P = 0.615). Sex-stratified estimates were similarly not statistically significant: HR 1.22 (95 % CI 0.81–1.82, P = 0.34) in women and HR 1.40 (95 % CI 0.95–2.07, P = 0.085) in men.

Race/ethnicity did not modify the association between PRWP and all-cause mortality (likelihood-ratio P = 0.60). Race-specific hazard ratios were 1.22 (95 % CI 0.80–1.86) for White participants, 0.45 (0.06–3.25) for Chinese American, 1.42 (0.94–2.15) for African American, and 1.11 (0.41–2.98) for Hispanic participants.

DISCUSSION

In this community-based cohort of more than six thousand adults initially free of clinical cardiovascular disease, isolated poor R-wave progression was present in 3.2% of participants. After fourteen years of surveillance and comprehensive adjustment for traditional risk factors, age, sex and self-reported ethnicity, PRWP was not associated with all-cause mortality or major adverse cardiovascular events (MACE). Adding sex- and race-specific interaction terms left the null finding unchanged.

The Health 2000 survey reported that PRWP doubled total and cardiovascular mortality in women over six years, even after multivariable adjustment.(1) Schröder and colleagues linked PRWP to sudden cardiac death (SCD) in the 24-year Mini-Finland follow-up (HR 2.13), together with elevated risks of cardiac death (HR 1.75) and all-cause mortality (HR 1.29). Notably, their CAD subgroup (n = 807) showed an even stronger hazard: PRWP tripled SCD (HR 2.62) and nearly doubled cardiac mortality (HR 1.71), associations that persisted after removal of Q-wave infarcts (HR 2.96 for SCD). By contrast, their CAD-free subgroup displayed no excess SCD risk and presented increase in cardiac death only (HR 1.64). MESA excluded baseline CAD and prior MI, thereby eliminating the structural substrate that appears to convert a low-voltage precordial pattern into a malignant marker. Without that substrate, PRWP was prognostically silent.

The discrepant prognostic findings among the Health 2000 survey(1), the Mini-Finland study(2), and the present MESA analysis can be attributed to marked differences in the underlying study populations. First, coronary artery disease status diverged. Health 2000 and Mini-Finland enrolled participants irrespective of prevalent CAD, and the latter confirmed angiographic disease in approximately one eighth of its cohort. MESA, in contrast, excluded any clinical CAD at baseline. The Finnish reports therefore evaluated a population in which PRWP frequently co-existed with established myocardial scar or ischemia, whereas MESA assessed PRWP in the absence of overt structural heart disease.

Second, baseline age distributions were dissimilar. Health 2000 and Mini-Finland both began follow-up at a mean age of roughly 51 years, whereas the

median age of the MESA PRWP group was 63 years. Despite this older starting
point—and thus higher absolute risk—MESA showed no excess mortality or
MACE associated with PRWP, indicating that age alone does not account for
the Finnish associations once CAD is removed.

Third, exposure to tobacco varied. Regular smoking was present in about 30 %
of PRWP men and 20 % of PRWP women in Health 2000, and a comparable
prevalence was recorded in Mini-Finland among participants without
angiographic CAD. In MESA only 23 % of PRWP cases were current smokers,
and inclusion of smoking status in the multivariable model further attenuated the
hazard ratio.

Finally, MESA uniquely captured self-reported emphysema, a condition that can
depress anterior voltages via lung hyperinflation. Emphysema was reported by
8 % of PRWP cases versus 1 % of controls, and adjustment for this variable,
together with smoking, moved the point estimate closer to unity. Neither Finnish
study collected systematic data on chronic obstructive lung disease. Although
advanced emphysema with cor pulmonale can produce rapid R-wave
progression by inducing right-ventricular hypertrophy, our emphysema data
were self-reported and baseline echocardiography was unavailable, limiting
assessment of that mechanism. Additionally, pulmonary hyperinflation could
plausibly diminish R wave amplitudes in precordial leads and generate
PRWP.(6) Future research could integrate lung-volume metrics or CT-based
markers with spirometry to determine whether physiologic hyperinflation is a
driver of reduced anterior voltages and apparent PRWP.

The present findings are also consistent with the absence of credible diagnostic
evidence.(7) In a recent scoping review, we sought studies that could quantify
the accuracy of PRWP for detecting prior anterior myocardial infarction.(3)
Every eligible research displayed severe selection bias: Zema's studies enrolled
only patients who already had PRWP and then looked for scar by angiography
or vectorcardiogram, but lacking a true control group with normal R-wave
progression. As a result, the published "sensitivities" and "specificities" are
inherently biased and essentially uninterpretable, leaving the true diagnostic
accuracy of PRWP for old anterior infarction unknown.

Taken together, these findings indicate that the prognostic signal attributed to
PRWP in earlier work is not intrinsic to the voltage pattern itself but rather to the

clinical setting in which the pattern was recorded. In a cohort stringently free of overt CAD—and rigorously adjusted for smoking and pulmonary hyperinflation—PRWP behaves as a benign ECG variant. Our null findings call into question the current practice of automatically flagging isolated PRWP as 'abnormal' on computer-generated ECG reports. When the pattern appears in patients without established CAD or overt structural heart disease, additional testing is unlikely to change management. This contention is consistent with the low positive predictive value (≈7 %) for angiographic CAD reported in population-based studies(8) and highlights the risk of unnecessary downstream investigations

Future directions

First, prospective cohorts should record electrode-position metadata or use body-surface mapping to establish the temporal stability of PRWP and distinguish true electrical change from placement artefact. Second, studies that pair precordial voltages with lung-volume surrogates—thoracic CT metrics, formal spirometry, or impedance plethysmography—are needed to clarify whether physiologic hyperinflation, rather than myocardial injury, is the dominant driver of reduced anterior voltage in community settings. Beyond these technical issues, high-quality diagnostic-accuracy research is needed. Specifically, adequately powered cohorts with a uniform PRWP definition should test its value for (a) detecting previous anterior myocardial infarction against a gold-standard imaging reference, (b) identifying reduced left-ventricular ejection fraction, and (c) flagging infiltrative or genetic cardiomyopathies in which low precordial voltages may precede overt structural change. Together, these lines of inquiry will determine whether PRWP deserves a place in modern risk algorithms or should be regarded as a benign variant when unaccompanied by other clinical cues.

Limitations

Several considerations must be acknowledged. First, PRWP was ascertained from a single baseline tracing; transient lead misplacement or day-to-day

biologic variability could have misclassified a small fraction of participants.
Although MESA technicians followed a standardized electrode-placement
protocol and quality audits revealed <2 % gross errors, even minor cranial
displacement of V_1/V_2 can convert a normal anterior pattern into PRWP.
While sequential ECGs are available in MESA, we did not model the
development or resolution of PRWP over time. Incident PRWP on follow-up
tracings may simply reflect changes in lead placement rather than new
myocardial injury; a rigorous longitudinal analysis would therefore require
electrode-position metrics that are not part of the dataset.

Second, R-wave amplitude is influenced by thoracic impedance and lung
volume. Conditions that increase chest wall thickness or hyperinflate the
lungs—obesity, chronic obstructive pulmonary disease, emphysema—were not
fully captured in baseline covariates and could have attenuated anterior
voltages independent of myocardial substrate. Although spirometry was
available for a subset of participants, spirometry alone cannot characterize
hyperinflation, so we did not interpret spirometric values as definitive evidence
of hyperinflation or emphysema.

Third, only 202 individuals met the PRWP criterion, limiting power for granular
subgroup analyses—particularly in men and within individual race/ethnicity
strata. Finally, although the extensive covariate set and stability across
sensitivity models argue against major confounding, residual or unmeasured
factors cannot be fully excluded in any observational analysis.

Conclusions

In a contemporary, multi-ethnic cohort of 6,323 adults who were free of clinical
cardiovascular disease at enrollment, isolated poor R-wave progression was
uncommon (3.2 %) and—for up to 14 years of follow-up—carried no
independent association with either all-cause mortality or major adverse
cardiovascular events after adjustment for age, sex, race/ethnicity, hypertension
and diabetes. Additional adjustment for the two imbalanced, biologically
plausible confounders—current smoking and self-reported emphysema—further
attenuated the already-neutral point estimates, and a formal interaction test
showed no meaningful difference in risk between women and men. Earlier

positive studies appear driven by populations enriched for coronary disease and

other high-risk features.

REFERENCES

1. Anttila I, Nikus K, Nieminen T, Jula A, Reunanen A, Salomaa V, et al. Prevalence and prognostic value of poor R-wave progression in standard resting electrocardiogram in a general adult population. The Health 2000 Survey. Ann Med. março de 2010;42(2):123–30.

2. Schröder LC, Holkeri A, Eranti A, Haukilahti MAE, Kerola T, Kenttä TV, et al. Poor R-wave progression as a predictor of sudden cardiac death in the general population and subjects with coronary artery disease. Heart Rhythm. 15 de fevereiro de 2022;19(6):952–9.

3. de Alencar JN, Amorim EF, Scheffer MK, Felicioni SP, De Marchi MFN. Poor evidence for poor R wave progression in coronary disease: A scoping review. J Electrocardiol. 1º de maio de 2024;84:145–50.

4. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 1º de novembro de 2002;156(9):871–81.

5. Blaha MJ, DeFilippis AP. Multi-Ethnic Study of Atherosclerosis (MESA). JACC. 29 de junho de 2021;77(25):3195–216.

6. Rodman DM, Lowenstein SR, Rodman T. The electrocardiogram in chronic obstructive pulmonary disease. J Emerg Med. 1990;8(5):607–15.

7. Gami AS, Holly TA, Rosenthal JE. Electrocardiographic poor R-wave progression: analysis of multiple criteria reveals little usefulness. Am Heart J. julho de 2004;148(1):80–5.

8. Kim SH, Kwak MH, Kim HJ, Nam GB, Choi KJ, Kim YH. Prevalence and positive predictive value of poor R-wave progression and impact of the cardiothoracic ratio. Korean Circ J. 2009/10/28 ed. outubro de 2009;39(10):418–22.

Sources of Funding

440 The Multi-Ethnic Study of Atherosclerosis (MESA) is supported by contracts
441 from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes
442 of Health. The content is solely the responsibility of the authors and does not
443 necessarily represent the official views of the NHLBI or the National Institutes of
444 Health.
445

Acknowledgments

447 We thank the MESA investigators, staff, and participants for their valuable
448 contributions. A full list of participating MESA investigators and institutions is
449 available at http://www.mesa-nhlbi.org.

 # TABLES

 TABLE 1

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal R-wave progression N = 6,121[1]	PRWP N = 202[1]	P (adj.)*
Age (yr)	61.8 (10.2)	63.0 (10.5)	0.123
Body-mass index (kg/m²)	28.3 (5.4)	28.3 (6.9)	0.823
Total cholesterol (mg/dL)	194.7 (35.7)	191.3 (32.1)	0.049
LDL cholesterol (mg/dL)	117.7 (31.6)	112.1 (28.2)	0.014
HDL cholesterol (mg/dL)	51.0 (14.8)	54.9 (15.7)	0.031
Physical activity (h/day)	12.6 (5.9)	12.6 (5.3)	0.877
QRS duration (ms)	91.3 (9.6)	91.6 (10.1)	0.062
Sex			<0.001
Female	3,291 (54%)	136 (67%)	
Male	2,830 (46%)	66 (33%)	

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal R-wave progression N = 6,121[1]	PRWP N = 202[1]	P (adj.)*
Ethnicity			<0.001
White	2,295 (37%)	95 (47%)	
Chinese American	759 (12%)	10 (5.0%)	
African American	1,674 (27%)	76 (38%)	
Hispanic	1,393 (23%)	21 (10%)	
Hypertension	2,679 (44%)	103 (51%)	0.150
Blood-pressure JNC category			0.158
Optimal	2,604 (43%)	78 (39%)	
Normal	1,042 (17%)	31 (15%)	
High-Normal	949 (16%)	28 (14%)	
Stage 1 HTN	1,091 (18%)	40 (20%)	
Stage 2 HTN	314 (5.1%)	21 (10%)	
Stage 3 HTN	119 (1.9%)	4 (2.0%)	

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal R-wave progression N = 6,121[1]	PRWP N = 202[1]	P (adj.)*
Diabetes			0.774
Normal	4,533 (74%)	149 (74%)	
Impaired fasting glucose	836 (14%)	24 (12%)	
Diabetes (untreated)	162 (2.6%)	5 (2.5%)	
Diabetes (treated)	590 (9.6%)	24 (12%)	
Smoking status			<0.001
Never	3,106 (51%)	84 (42%)	
Former	2,217 (36%)	71 (35%)	
Current	780 (13%)	46 (23%)	
Self-reported emphysema			<0.001
No	6,031 (99%)	186 (92%)	
Yes	82 (1.3%)	16 (7.9%)	

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal R-wave progression N = 6,121[1]	PRWP N = 202[1]	P (adj.)*
Unknown	7 (0.1%)	0 (0%)	
β-Blocker medication	535 (8.7%)	22 (11%)	0.433
Atrial fibrillation	1 (<0.1%)	0 (0%)	0.979
LVH (ECG-based)	610 (10.0%)	21 (10%)	0.797
LVH (CMR-based)	1,340/4,525 (30%)	42/138 (30%)	0.679

[1] Mean (SD); n (%); n/N (%)

Legend: Baseline Characteristics by Poor R-Wave Progression Status.
Continuous variables are reported as mean (SD); categorical variables as n
(%), except LVH (CMR-based), shown as n/total (%) to denote the number with
cardiac-MRI data available.

PRWP is defined as R-wave amplitude ≤ 3 mm in lead V3 and R-wave V3 > R-
wave V2.

P (adj.) values come from logistic-regression models that provide: (i) Age
adjusted for sex; (ii) Sex adjusted for age; (iii) every other variable adjusted for
both age and sex.

LVH (CMR-based): LV mass index > 90 g/m² (men) or > 77 g/m² (women).

LVH (ECG-based): positive Sokolow-Lyon or Peguero-Lo Presti voltage
criterion.

JNC = Joint National Committee blood-pressure category.

TABLE 2.

Event (priority order)	PRWP (n = 202)	No PRWP (n = 6,121)	Total (n = 6,323)	p-value[1]
Cardiovascular death	16 (7.9 %)	299 (4.9 %)	315	0.074
Non-fatal MI	3 (1.5 %)	122 (2.0 %)	125	0.800
Coronary revascularization	6 (3.0 %)	258 (4.2 %)	264	0.489
Hospitalization for CHF	13 (6.4 %)	201 (3.3 %)	214	0.0251

Legend: Hierarchical First-Occurrence Major Adverse Cardiovascular Events in
the Multi-Ethnic Study of Atherosclerosis Cohort. Major adverse cardiovascular
events (MACE) include cardiovascular death, nonfatal myocardial infarction,
coronary revascularization (percutaneous coronary intervention or coronary
artery bypass graft), and heart failure hospitalization. Events are hierarchical,
counted as the first occurrence per participant in the order of cardiovascular
death, nonfatal myocardial infarction, coronary revascularization, and heart
failure hospitalization. Cases are participants with poor R-wave progression
(PRWP), defined as an absolute R-wave amplitude ≤ 3 mm in lead V3 and
larger than the absolute R-wave amplitude in lead V2; Controls are participants
without PRWP. Percentages are calculated as the proportion of events within
each group (Cases, Controls, or Total). P-values are derived from chi-square
tests applied to 2x2 contingency tables comparing the proportion of each event
between Cases and Controls. [1]p-values compare the proportion of each event
between PRWP cases and controls; Pearson's χ^2 test was used when all
expected cell counts were ≥ 5, otherwise Fisher's exact test was applied.

FIGURES

Figure 1.

Legend: Study flow diagram.

Figure 2.

Adjusted Survival: All-cause mortality

Legend: Model-adjusted survival for all-cause mortality. Survival probabilities
for participants with normal R-wave progression (Controls, blue) and those with
poor R-wave progression (PRWP, red) were estimated from the fully adjusted
Cox model (age, sex, self-identified race/ethnicity, hypertension, diabetes).
Shaded ribbons represent point-wise 95 % confidence intervals obtained by
direct standardization of the covariate distribution. Numerical numbers-at-risk
are omitted because direct standardization averages person-time across the
entire cohort.

Figure 3.

Legend: Model-adjusted survival for major adverse cardiovascular events
(MACE). Curves and confidence bands were derived exactly as in Figure 2,
using time to first MACE (cardiovascular death, non-fatal myocardial infarction,
coronary revascularization, or heart-failure hospitalization) as the outcome.
Adjustment variables and graphical conventions are identical to those described
for Figure 2.

Adjusted Survival: MACE